Clinical trial · Observational
Para-Aortic Lymph Nodal Staging & Evaluation of Treatment Outcome by 18F FDG-PET in Advanced Cancer Cervix
Para-Aortic Lymph Nodal Staging and Evaluation of Treatment Outcome by 18F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Advanced Cervical Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
18F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Imaging has been extensively used in the evaluation of various malignancies and is rapidly being recognized as a mandatory investigations. 18F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Imaging has also been tried in cervical cancers with excellent results for detection of both pelvic and extra-pelvic disease in terms of sensitivity and specificity. Till date, PET Imaging has been reported to have highest sensitivity and specificity for detection of disease and treatment failures compared to other non-invasive investigations available. Treatment decisions (Localized RT Vs Extended RT) will be according to the results of PET Scans. The treatment response, outcome and follow-up will be labelled according to the PET Scan results and will be directed for treatment accordingly.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of Cervix | Malignant Cervical Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET IMAGING | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- PET Scan for Para-Aortic Staging in Carcinoma Cervix
- timeFrame
- 5 years
- measure
- Clinical (FIGO), MRI, and PET - Abdomen and Pelvis Correlation
- timeFrame
- 5 years
- measure
- Volumetric Correlation of Local Disease by PET and MRI
- timeFrame
- 5 years
- measure
- Radiotherapy Response Evaluation and Post therapy Surveillance by serial PET Scans
- timeFrame
- 5 years
Secondary outcomes (1)
- measure
- overall survival
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven squamous carcinoma or adenocarcinoma of cervix * Performance index WHO grade 0 or 1 * Patients below 65 years of age * FIGO Stage IIB / IIIB * Normal ECG and Cardiovascular system * Normal hematological parameters * Normal renal and liver function tests * Normal Blood Sugar levels / Controlled Diabetes Exclusion Criteria: * Co-morbid conditions like medical renal disease * Past History of Phobia for MRI Examination * Medical or Psychological condition that would preclude Investigations / Treatment * H/o Previous treatment / Pregnancy * Patient unreliable for treatment completion and follow-up Investigations.
References
Publications (0)
Data not yet available